Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome
Year: 2007
Type: article
Abstract: Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome characterized by dislipidemia and insulin resistance. We hypothesized that ezetimibe, an inhibitor of NPC1L1, improves these metabolic disorders in Zucker obese fatty rats (ZOF). Ezetimibe significantly lowered total cholesterol and triglycerides in ZOF with prominent reduction in the remnant lipoprotein fraction and small dense low density lipoprotein fraction. Moreover, lipid deposition and fibrosis of liver were decreased by ezetimibe. Interestingly, ezetimibe improved insulin and plasma glucose response after intraperitoneal glucose injection. Further, ezetimibe enhanced insulin signaling in cultured hepatocytes. Our results indicate the potential of ezetimibe in treating the metabolic syndrome and NAFLD.
Source: FEBS Letters
Authors: Michiyo Deushi, Mitsunori Nomura, Akio Kawakami, Mihoko Haraguchi, Mizuho Ito, Mitsuyo Okazaki, Hideto Ishii, Masayuki Yoshida
Institution: Tokyo Medical and Dental University
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Ono Medical Research Foundation
OpenAlex ID: W2166131374
